fbpx

Analyze.

Reset.

Revolutionize.​

Virtual KOL Event Replay

'1104: A First-in-Class Peptide for Eosinophilic Esophagitis (EoE) and Allergic Disease

Recorded on Tuesday, August 29, 2023

Watch the Replay

About

If you’re looking for a typical biotechnology company, you’ve come to the wrong place.

We are a revolutionary biotherapeutics company and our mission is to revolutionize autoimmune and allergic disease treatment by resetting the immune system for superior long-term disease remission.

How?

By developing therapies that achieve superior long-term disease remission from less frequent chronic dosing and without suppression of the immune system. A goal that others haven’t been able to reach.

Why?

Existing therapies for autoimmune and allergic diseases require frequent chronic dosing, provide only short-term disease remission in a limited number of patients and suppress the immune system, ultimately putting patients at risk of developing serious infections and life-threatening side effects.

Product Development Landscape

Product Development Landscape

Our two platform drug candidates, ‘1104 and ‘1805, reset the immune system after only a single administration in an unmatched way. They have demonstrated unique efficacy and safety in preclinical and human studies – without immune suppression. Given our disease-agnostic approach, we are uniquely positioned as revolutionaries in the development of drugs for various autoimmune and allergic diseases.

Revolo Clouds
‘1104
is a first-in-class peptide derived from the immuno-regulatory protein mTB chaperonin 60.1. We are advancing ‘1104 through Phase 2 trials in patients with eosinophilic esophagitis (EoE), allergic disease and allergic asthma.
More about ‘1104
‘1805
is a modified analogue of the endogenous immune-regulatory binding immunoglobulin protein (BiP), a key player in immune function. We are advancing ‘1805 through two Phase 2 trials: the first is an additional trial in patients with moderate to severe rheumatoid arthritis and the second in patients with ulcerative colitis.
More about ‘1805
Previous slide
Next slide

news

Latest News

November 7, 2023 | Press Release

Revolo Biotherapeutics Presents New Data on ‘1805 at the American College of Rheumatology Convergence 2023 Annual Conference

– New preclinical data further elucidate ‘1805’s mechanism of action ...

October 25, 2023 | Press Release

Revolo Biotherapeutics Announces Data from Study of ‘1104 in Atopic Adults

– Treatment with ‘1104 demonstrated a rapid reduction in intradermal ...
View All News

Investors

Revolo Bio is a privately held, venture-funded biotechnology firm engaged in unique and revolutionary therapies. If you’d like to get more information, we’d love to provide it, so don’t hesitate to contact us!

See our Investor deck here.

Join Us

The Revolo Bio team is always interested in hearing from exceptional candidates who are eager to join our team. Please contact us for more details about a career with Revolo Bio.

Contact Us

We are always looking to revolutionize treatment paradigms and are happy to chat with you about yours or ours. Interested? We are!

Contact Us
Facebook-f Linkedin-in Instagram

900 Camp Street
New Orleans, LA 70130
United States

Windsor House, Station Court, Station Road
Great Shelford, Cambridgeshire CB22 5NE,
United Kingdom

© 2022 Revolo Biotherapeutics | Privacy & Cookie Policy

Scroll to Top

Tunde Otulana, M.D.

Non-Executive Director

Tunde is currently the Chief Medical Officer of Veloxis Pharmaceuticals in North Carolina, USA since August 2020. Prior to Veloxis he was Senior Vice President and Chief Medical Officer at Mallinckrodt Pharmaceuticals. His career, which spans about 30 years in industry, government and academia, includes leadership roles at Boehringer Ingelheim Pharmaceutical Inc. and the US Food and Drug Administration (“FDA”). Tunde is a physician trained in Pulmonary and Critical Care Medicine.

Linkedin-in

Beth Alley

VP of Regulatory Affairs

Beth Alley has over 20 years of experience within the biopharmaceutical industry in regulatory affairs, commercial strategy, and medical writing throughout all phases of drug development. Her primary areas of focus have been in development of biologics for treatment of autoimmune, inflammatory, and infectious diseases.

Linkedin-in

Glen Giovanetti

Non-Executive Director

Glen Giovanetti has more than 35 years of experience in strategy and operational leadership in the life science industry as well as in financial governance, risk and reporting as EY’s Global Biotechnology Sector Leader and Life Sciences Sector Leader. He currently serves on the Board of Directors of Life Science Cares, Teon Therapeutics and XW Pharma.

Linkedin-in

Marla S. Persky

Non-Executive Director

Marla S. Persky currently serves as the chief executive officer and president of WOMN LLC. She has more than 25 years of international senior business and legal experience in the pharmaceutical industry having held numerous business and legal positions at Boehringer Ingelheim and Baxter International. She currently serves on the Boards of Directors of Xeris Pharmaceuticals, YGEIA Consulting Group, Primary Stages, World Neighbors and A Better Chance in Ridgefield.

Linkedin-in

Dora Rau

Senior Vice President, Quality

Dora Rau brings 25 years of experience in development and commercial operations for drugs, biologics, devices and combination products to the team. She has held numerous executive-level quality positions, with expertise in building quality systems and in leading teams to attain successful regulatory authority inspection outcomes and product approvals.

Linkedin-in

Jonathan Gold

Chief Financial Officer

Over the last 25 years, Jonathan Gold has been an institutional venture capitalist, a public fund manager, a founder, an operating executive, and a board member for companies across sectors including life sciences. In those roles, he was active in the development, financing and mergers and acquisitions for numerous public and private companies.

Team Members
Linkedin-in

Michael Albisser

Non-Executive Director​

Michael is a partner of Metellus, a Zurich and London-based venture capital firm investing in technology and life sciences with ground-breaking potential. Having more than 25 years of experience in the finance area he is responsible for finance, tax, and deal structures. He serves on the board of various venture-backed companies.

Linkedin-in

Dr. Isaac Cheng, m.d.

Non-Executive Director

Dr. Isaac Cheng is currently an investment professional at Morningside, a venture capital and private equity institution based in Boston USA, and Shanghai China. Dr. Cheng focuses primarily on biopharmaceutical and healthcare investments. He has served on numerous public and private company boards.

Linkedin-in

Peter Greenleaf

Chairman

Peter Greenleaf currently serves as the chief executive officer (CEO) and member of the Board of Directors of Aurinia, (NASDAQ: AUPH / TSX: AUP), an autoimmune therapeutics company. He has held several other CEO and chairman roles. He is also currently a member of the Board of Directors of Antares Pharmaceuticals, Inc. (NASDAQ: ATRS) and Chairman of the Board of Directors of Biodelivery Sciences International, Inc. (NASDAQ: BDSI).

Linkedin-in

Marylyn Rigby

SVP of Marketing and Investor Relations

Marylyn Rigby is an experienced pharmaceutical, biotech, and drug delivery professional. In addition to her expertise in marketing, public and investor relations, she has a successful track record with business development, licensing, public and private equity financing, strategy and other key corporate functions.

Linkedin-in

Nancy Vinh

SVP of Clinical Operations

Nancy Vinh brings over 20 years of experience in managing early and late phase, international clinical trials for drugs, biologics, cell therapy and combination products across a wide range of therapeutic areas to the team. She has served as head of clinical operations and led registrational and label expansion trials execution.

Team Members
Linkedin-in

Dr. Clare Burgess

Chief Development Officer

Dr. Clare Burgess has 24 years of experience in clinical drug development as a pharmacologist and has worked across a wide range of therapeutic areas within the pharmaceutical industry. She has held multiple leadership roles and has led multidisciplinary teams across the world.

Linkedin-in

Jeff Myers, m.d., ph.d

Chief Medical Officer

Jeff Myers, M.D., Ph.D., has 20 years of experience in medical affairs, regulatory and clinical development within the biopharmaceutical industry, with focuses on cardiovascular, pulmonary, oncology, and inflammatory diseases.

Before entering the industry, he practiced as a congenital cardiac surgeon and served as the chief of pediatric cardiac surgery at Massachusetts General Hospital and as Associate Professor of Surgery at Harvard Medical School.

Team Members
Linkedin-in

Dr. Roly Foulkes

Chief Scientific Officer

A true drug discoverer, Dr. Roly Foulkes has 25 years of experience building and delivering innovative therapeutic portfolios within the immunology and inflammatory disease space. He has a strong record advising small and medium sized immunology biopharma companies in developing competitive therapeutic strategies and bringing new innovative molecules to the clinic.

Team Members
Linkedin-in

Jones w (woody) Bryan, ph.d.

President & Chief Business Officer

Jones (Woody) Bryan, Ph.D., brings almost 30 years of experience in the healthcare industry to the team, having led successful business development operations in both private and public pharma and biotech companies.

Team Members
Linkedin-in

Jonathan Rigby, mba

Group Chief Executive Officer

As employee #1 of Revolo Biotherapeutics in the US, Jonathan Rigby has led the company through substantial and rapid growth. He brings three decades of experience creating value and opportunities for companies in the pharmaceutical, biotech and drug delivery technology industry.

Team Members
Linkedin-in